Browse the evidence

Intermittent administration of senolytic drugs (Dasatinib + Quercetin) or genetic clearance of senescent cells alleviates obesity-induced metabolic dysfunction, including insulin resistance and glucose intolerance, in obese mice.

This research suggests that targeting senescent cells (cells that have stopped dividing and secrete inflammatory factors) using specific drug combinations (like Dasatinib and Quercetin) or genetic methods can improve metabolic health in obesity. While not yet a standard human treatment, it highlights senolytics as a potential future therapy for obesity-related diabetes and inflammation.

Prenatal exposure to severe famine during early gestation (conception to ~10 weeks) causes persistent, intermediate-level DNA methylation changes at specific regulatory regions (P-DMRs) that are associated with adverse metabolic phenotypes (higher LDL cholesterol) and growth outcomes (birth weight) in later life.

If you were exposed to severe nutritional deprivation during the first 10 weeks of pregnancy, you may have a higher risk of elevated LDL cholesterol and altered metabolic regulation due to persistent changes in your DNA methylation patterns. This does not mean you are destined for poor health, but it does suggest that monitoring your lipid profile and metabolic health is crucial. The study highlights specific genes (INSR, CPT1A) involved in insulin signaling and fatty acid oxidation, suggesting that lifestyle interventions focusing on metabolic health (diet, exercise) may be particularly important for this population to counteract these early-life epigenetic marks.

Genetic polymorphisms in PNPLA3 (rs738409) and TM6SF2 (rs58542926) are associated with an increased risk of advanced fibrosis in NAFLD patients, independent of metabolic variables.

If you have a family history of fatty liver or known genetic variants like PNPLA3, you may be at higher risk for fibrosis. This means you should be more vigilant about managing metabolic health (weight, diabetes, blood pressure) as these factors interact with your genetics to drive progression.

Systolic blood pressure (SBP) shows no or weak correlation with national income, urbanization, or food expenditure share, remaining high in some low-income countries and variable in high-income countries.

Do not assume low blood pressure risk in low-income settings. Population-level interventions for blood pressure (e.g., salt regulation) are needed globally, regardless of economic status.

Exposure to the environmental contaminant tributyltin chloride (TBT) acts as a potent inducer of adipogenesis in vertebrates by functioning as a dual nanomolar-affinity ligand for retinoid X receptor (RXR) and peroxisome proliferator-activated receptor gamma (PPARγ), leading to increased lipid accumulation and adipose mass.

This research identifies a specific environmental chemical, tributyltin chloride (TBT), as a direct cause of increased fat mass in vertebrates. TBT acts by hijacking key fat-regulating receptors (RXR and PPARγ). While this does not provide a direct lifestyle intervention, it highlights that reducing exposure to organotin contaminants (found in some seafood, plastics, and treated materials) may be a relevant factor in obesity prevention strategies alongside diet and exercise.

By 2030, approximately 50% of US adults are projected to be obese, and 78% will be overweight or obese, with significant disparities across racial and ethnic groups.

Prepare for a future where half of adults are obese and nearly 80% are overweight. This is not a distant threat but a current trajectory. Focus on culturally-tailored, sustainable interventions to mitigate personal risk and contribute to broader public health efforts.

Reduced sensitivity to light due to lens yellowing and reduced SCN neuronal coupling contributes to the desynchronization of peripheral clocks and weakened circadian output in older adults.

Your eyes let in less blue light as you age, weakening your body's time signal. Maximizing morning outdoor light exposure can help compensate for this reduced sensitivity and strengthen your circadian rhythm.

High-level gastrointestinal expression of bacterial bile salt hydrolase (BSH) enzymes significantly reduces host weight gain, plasma cholesterol, and liver triglycerides in mice.

This research suggests that increasing the activity of bile salt hydrolase (BSH) in the gut, potentially through specific probiotic bacteria (like certain Lactobacillus strains), may help reduce weight gain and lower cholesterol. While this is a mouse study, it highlights the gut microbiome as a target for metabolic health. You might explore probiotics known for BSH activity, but consult a doctor before making changes, especially if you have existing metabolic conditions.

Rimonabant, a CB1 receptor antagonist, was withdrawn due to an increased risk of serious psychiatric adverse events, including depression and suicidal ideation.

Rimonabant was withdrawn from the market because it significantly increased the risk of depression and suicidal thoughts compared to placebo.

Overexpression of the SIRT1 deacetylase suppresses intestinal tumorigenesis and colon cancer growth in vivo by directly deacetylating and inhibiting the transcriptional activity of beta-catenin.

This research suggests that the biological pathway involving SIRT1 may help protect against colon cancer by turning off a key driver of tumor growth (beta-catenin). While this paper uses genetic overexpression in mice, it supports the idea that maintaining healthy SIRT1 function (potentially through calorie restriction or other means) might be beneficial for cancer prevention. It does not recommend specific supplements or doses for humans.

Islet amyloid polypeptide (IAPP) aggregation into small soluble oligomers causes beta-cell death via membrane disruption and oxidative stress, contributing to the loss of beta-cell mass in type 2 diabetes.

This research highlights that beta-cell failure in type 2 diabetes is actively driven by toxic protein aggregates (IAPP), not just passive aging. This suggests that therapies targeting amyloid formation (like pramlintide analogs or small molecule inhibitors) could preserve remaining beta-cell function, offering a pathway to slow disease progression beyond just lowering blood sugar.

Small, soluble IAPP oligomers (prefibrillar assemblies) are the primary cytotoxic species responsible for beta-cell death, whereas mature amyloid fibrils are less cytotoxic.

Therapies should target the early formation of soluble IAPP aggregates, not just the mature amyloid deposits, as the early aggregates are the primary cause of cell death.

Anabolic steroids exert their effects through multiple mechanisms including androgen receptor modulation, anticatabolic effects via glucocorticoid receptor interference, and non-genomic pathways.

Anabolic steroids work through complex hormonal pathways, including receptor modulation and anticatabolic effects, which contribute to muscle growth and training motivation.

Overexpression of the short p53 isoform (p44) in mice accelerates aging and reduces lifespan by hyperactivating the IGF signaling axis, which triggers a kinase cascade that clamps cell proliferation via p21Cip1 induction.

This research highlights the complexity of the p53 pathway in aging. While reducing IGF signaling is often associated with longevity, this study shows that hyperactivating it via specific p53 isoforms can accelerate aging. This suggests that maintaining a balance between p53 isoforms is crucial for longevity, rather than simply maximizing or minimizing p53 activity.

Pharmacological inhibition or genetic ablation of enzymes controlling sphingolipid synthesis (specifically Serine Palmitoyltransferase and Dihydroceramide Desaturase 1) ameliorates insulin resistance, atherosclerosis, and cardiomyopathy in rodent models.

This research suggests that the type of fat you consume matters more than just the total amount, specifically regarding how it affects your body's insulin sensitivity. Saturated fats appear to trigger the production of specific lipids (ceramides) that block insulin action, contributing to metabolic disease. While this is proven in animals, it implies that dietary quality, particularly the ratio of saturated to unsaturated fats, is a critical lever for metabolic health.

Probiotic supplementation does not significantly alter the overall composition, alpha-diversity, or richness of the fecal microbiota in healthy adults compared to placebo.

If you are healthy, taking probiotics is unlikely to change your gut bacteria composition or diversity. The marketing promise of 'rebalancing' the microbiota in healthy individuals is not supported by current high-quality evidence. Focus on dietary fiber and overall diet quality for microbiota health instead.

In vivo expression of p16INK4A in human skin significantly increases with chronological age, serving as a robust biomarker for intrinsic cellular aging.

This research confirms that cellular aging in skin is a measurable biological process, not just wear and tear. The accumulation of p16INK4A-positive cells is a key indicator of this process. While this paper identifies the marker, it does not offer a direct treatment. However, it validates the importance of monitoring cellular health and suggests that interventions targeting senescence (senolytics) or gene regulation (like BMI1) may be relevant for longevity strategies.

Circulating levels of miR-122 are significantly elevated in patients with non-alcoholic steatohepatitis (NASH) compared to healthy controls and those with simple steatosis, serving as a biomarker for disease severity.

For individuals with fatty liver, elevated circulating miR-122 levels may indicate a progression to more serious liver inflammation (NASH). While not yet a standard clinical tool, this biomarker shows promise as a non-invasive alternative or complement to liver enzymes for assessing disease severity, potentially reducing the need for invasive biopsies in some cases.

Rapid catch-up weight gain during infancy (birth to 2 years) in small-for-gestational-age (SGA) children drives the subsequent development of central adiposity and insulin resistance between ages 2 and 4, despite normal overall weight and BMI trajectories.

For parents of small-for-gestational-age (SGA) infants, the rate of weight gain in the first two years of life is a critical predictor of future metabolic health. Rapid catch-up growth during this infancy period is strongly associated with increased abdominal fat and insulin resistance by age 4, even if the child's overall weight appears normal. Caregivers should monitor growth velocity and body composition during infancy, as this is the primary window for preventing adverse metabolic outcomes, rather than focusing solely on weight gain after age 2.

GLP-1 receptor activation inhibits beta-cell apoptosis through cAMP/PKA and PI3K/Akt signaling pathways, protecting beta-cells from cytokine and fatty acid-induced death.

GLP-1 helps beta-cells survive stress by activating survival pathways (Akt and CREB). This protection may help maintain insulin production in the face of metabolic stress.

GLP-2 administration promotes intestinal epithelial proliferation and regeneration, reducing apoptosis and improving outcomes in models of intestinal injury such as enteritis and mucositis.

GLP-2 helps the gut lining grow back and repair itself after injury from drugs or disease. This suggests potential utility in treating inflammatory bowel disease or chemotherapy-induced gut damage.

Genetic manipulations that interfere with dietary restriction-mediated lifespan extension (DR-essential genes) identify key pathways where DR acts, and some genes act as genetic DR mimetics by extending lifespan even without DR.

Research into DR-essential genes and genetic mimetics (like the growth hormone receptor) offers potential targets for pharmacological interventions that mimic the benefits of caloric restriction without the need for severe dietary restriction. This suggests future drugs could target these pathways to extend healthspan.

Genetic deletion of the insulin receptor substrate 1 (Irs1) gene extends median lifespan by 18% in female mice and delays multiple age-related biomarkers, including motor decline, immune senescence, and bone loss, despite the presence of lifelong insulin resistance.

This research identifies IRS1 signaling as a critical regulator of aging in mammals. While direct genetic manipulation is not possible for humans, it suggests that modulating this specific intracellular pathway could be a target for therapies to delay aging and age-related diseases, independent of improving insulin sensitivity.

Rapamycin extends mean and maximum life spans in genetically heterogeneous mice when administered in mid-to-late life, making it the most strongly supported mammalian longevity therapeutic.

Rapamycin is currently the most effective known drug for extending lifespan in animal models, working by inhibiting the mTOR growth pathway. However, it carries significant risks in humans, including immune suppression, metabolic disturbances, and wound healing issues. It is not currently recommended for healthy individuals seeking longevity, but research into safer analogs (rapalogs) or intermittent dosing strategies is ongoing.